Non-Invasive Prenatal Testing (NIPT)

Patient information

Non-invasive prenatal testing (NIPT) (also known as the Panorama Test, the Harmony Test, or the Verifi Test) analyses cell-free DNA circulating in the pregnant mother's blood. It is a new option in prenatal screening for Down syndrome (trisomy 21), and other fetal chromosomal conditions (such as trisomies 18 and 13 or X and Y chromosome problems).

This test can be requested for any singleton pregnancy, including in vitro fertilization (IVF) pregnancies with egg donors. It can also be requested for twin pregnancies conceived naturally or by IVF using the patient's own egg.

Your appointment for a Feal DNA test includes a blood test and an ultrasound scan to confirm dates and viability.

A simple blood draw from the mother's arm is then performed and this sample is shipped directly to the USA and results are back in 10 to 12 days*. If your result is not reassuring, Prof. Malone or Prof. Daly will arrange to call you to discuss the resuls in detail and advise you of further testing and consultation.

This consultation is available to you regardless of where in our network of Practioners your Fetal DNA test was performed. We have a network of GPs and Consultant Obstetricians around the country providing this service. Look at our map of Ireland to find your nearest provider.

About Non-Invasive Prenatal Testing

DNA from the fetus circulates in the mother's blood.Cell-free DNA (cfDNA) results from the natural breakdown of fetal cells (presumed to be mostly placental) and clears from the maternal system within hours of giving birth.

During a pregnancy, cfDNA can be tested to give the most accurate screening approach in estimating the risk of a fetus having a common chromosome condition sometimes called a trisomy. This occurs when there are three copies of a particular chromosome instead of the expected two. The test looks to detect the following trisomies:

  • Trisomy 21: is the most common trisomy at the time of birth. Also called Down syndrome, it is associated with moderate to severe intellectual disabilities and may also lead to digestive disease, congenital heart defects and other malformations.
  • Trisomy 18 (Edwards syndrome) and Trisomy 13 (Patau syndrome): are associated with a high rate of miscarriage. These babies are born with severe brain abnormalities and often have congenital heart defects as well as other birth defects. Most affected individuals die before or soon after birth, and very few survive beyond the first year of life.
  • Sex chromosome conditions: The sex chromosomes (X and Y) determine whether we are male or female. X and Y chromosome conditions occur when there is a missing, extra, or incomplete copy of one of the sex chromosomes. The Non-Invasive Prenatal Testing procedure can assess risk for XXX, XYY, XXYY, XXY (Klinefelter syndrome), and a missing X chromosome in a girl (Turner syndrome).

    There is significant variability in the severity of these conditions, but most individuals have mild, if any, physical or behavioural features. If the mother is interested in having this optional testing, she should talk with her healthcare provider to determine if it is right for her.
  Nifty Harmony Panorama
Results Available 14 Working days 12 Working days 8 to 10 Working days
Pregnacy (Weeks) 11 Weeks 10 Weeks 9 Weeks
Down Syndrome
Edward Syndrome
Patau Syndrome
Turner Syndrome
Sex of fetus (if requested)
IFV donor egg
IFV donor egg Twins


The testing is non-invasive: it involves taking a blood sample from the mother. The pregnancy is not put at risk of miscarriage, or from other adverse outcomes that are associated with invasive testing procedures such as amniocentesis.


Clinical studies have shown that the Non-Invasive Prenatal Testing procedure has exceptional accuracy for assessing fetal trisomy risk. A 'high risk' result is indicative of a high risk for a trisomy. The test identifies in singleton pregnancies more than 99% of fetuses with trisomy 21, 98% of fetuses with trisomy 18, and 80% of fetuses with trisomy 13, and 96% of fetuses with Turner Syndrome.

X and Y analysis provides >99% accuracy for fetal sex. Accuracy for detecting other sex chromosome anomalies varies by condition. After the test, the number of women required to have a CVS or an amniocentesis is less than 1%. It is important to note that if the test results show there is a high risk that the fetus has trisomy 21, 18, 13 or sex chromosome conditions, it does not mean that the fetus definitely has one of these conditions, although it is highly likely.

For this reason, in the event of a 'high risk' (or positive) result, follow-up testing by an invasive procedure is recommended. In the same way if the test results show that there is a'low risk' that the fetus has trisomy 21, 18, 13 or sex chromosome conditions, it is unlikely that the fetus has one of these conditions. However, there is a very small risk that not all trisomy fetuses will be detected.

All results should be interpreted by a clinician in the context of clinical and familial data. Patients should continue with their usual scan appointments following testing.

Who can have the test?

The Non-Invasive Prenatal Testing procedure can be performed for any woman with a pregnancy of at least 9 weeks' gestational age. It can also be ordered for all IVF singleton pregnancies, including those with egg donors. Samples from pregnant women with twins naturally conceived, or those conceived using the patient's own egg, are also accepted. This test does not assess risk for mosaicism, partial trisomies or translocations.

The results will be ready in approximately one to two weeks, at which time most women can have their 12-week scan for a detailed examination of the fetal anatomy, including measurement of nuchal translucency, nasal bone and other important factors. In this visit, patients can discuss the DNA and ultrasound results with their obstetricians.

On the basis of the NIPT result and the ultrasound findings, a patient can decide whether or not she wants to have an invasive procedure (for example, CVS or amniocentesis).

Repeat samples

There needs to be enough fetal DNA in the maternal blood to be able to provide a result. If there is insufficient fetal DNA in the sample (occurring in 3% of cases), another blood sample from the mother may be required. This will be processed in the laboratory at no extra charge.

What is the process?

Once the mother has taken an independent personal decision that she wants to have the non-invasive prenatal test performed, she will be asked to sign a consent form and her blood sample can be taken from a vein in her arm.

Who carries out the analysis of the test?

The sample and completed request form will be sent to the relevant laboratory, where the fetal DNA will be extracted from the blood sample, and a result will be provided.

Will the mother need to have any other tests?

Non-Invasive Prenatal Testing does not provide information on other rare chromosomal abnormalities. If the ultrasound scan shows a high nuchal translucency or other major physical defects such as brain abnormalities, heart abnormalities, the risk for some rare chromosomal defects may be high. In such cases, the mother may choose to have a CVS or an amniocentesis.

The Non-invasive prenatal test does not provide information on other physical defects such as spina bifida, or information on fetal growth. It is therefore advisable that the mother has all the usual ultrasound scans during her pregnancy

Transfer of the mother's information outside the European Union

For the purposes of carrying out NIPT, the mother's personal information may be transferred outside of the European Union, for example to the USA. Please be aware that the laws applicable to her personal data in the USA are different from those operating in the UK and Ireland.